Register to chat with like-minded investors on our interactive forums.

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Next >>

Date	Time	Source	Headline	Symbol	Company
11/24/2021	11:53AM	TipRanks	Berenberg Bank Reaffirms Their Hold Rating on AbbVie (ABBV)	NYSE:ABBV	AbbVie Inc
11/23/2021	8:15AM	PR Newswire (US)	AbbVie to Present at the Evercore ISI Conference	NYSE:ABBV	AbbVie Inc
11/23/2021	8:00AM	PR Newswire (US)	AbbVie to Present at the Piper Sandler Healthcare Conference	NYSE:ABBV	AbbVie Inc
11/19/2021	8:00AM	PR Newswire (US)	Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The 2021 American Society For Dermatologic Surgery Virtual Meeting	NYSE:ABBV	AbbVie Inc
11/18/2021	9:00AM	PR Newswire (US)	New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission	NYSE:ABBV	AbbVie Inc
11/18/2021	7:01AM	PR Newswire (Canada)	AbbVie annonce le premier remboursement provincial, au Québec, de VENCLEXTA® (vénétoclax) en association avec l'obinutuzumab pour le traitement des patients atteints de leucémie lymphoïde chronique n'ayant jamais été traités	NYSE:ABBV	AbbVie Inc
11/18/2021	7:01AM	PR Newswire (Canada)	AbbVie Announces First Provincial Reimbursement for VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia in Quebec	NYSE:ABBV	AbbVie Inc
11/18/2021	4:36AM	TipRanks	AbbVie’s Gets EC Approval for SKYRIZI	NYSE:ABBV	AbbVie Inc
11/17/2021	2:05AM	PR Newswire (US)	AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis	NYSE:ABBV	AbbVie Inc
11/15/2021	8:30AM	PR Newswire (US)	Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day	NYSE:ABBV	AbbVie Inc
11/10/2021	8:30AM	PR Newswire (US)	AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025	NYSE:ABBV	AbbVie Inc
11/10/2021	8:00AM	PR Newswire (US)	AbbVie to Present at the Wolfe Research Healthcare Conference	NYSE:ABBV	AbbVie Inc
11/09/2021	8:45AM	PR Newswire (US)	AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021	NYSE:ABBV	AbbVie Inc
11/09/2021	8:31AM	PR Newswire (US)	AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis	NYSE:ABBV	AbbVie Inc
11/08/2021	8:30AM	PR Newswire (US)	Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting	NYSE:ABBV	AbbVie Inc
11/08/2021	6:43AM	TipRanks	AbbVie Presents Data from Two Phase 3 Trials on Risankizumab	NYSE:ABBV	AbbVie Inc
11/05/2021	10:06AM	PR Newswire (US)	AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021	NYSE:ABBV	AbbVie Inc
11/04/2021	5:35PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
11/04/2021	9:05AM	PR Newswire (US)	AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting	NYSE:ABBV	AbbVie Inc
11/01/2021	8:31AM	PR Newswire (US)	AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR Convergence 2021	NYSE:ABBV	AbbVie Inc
11/01/2021	2:56AM	TipRanks	AbbVie’s 2021 Earnings Outlook Exceeds Estimates; Shares Up 4.6%	NYSE:ABBV	AbbVie Inc
10/29/2021	5:31PM	PR Newswire (US)	U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)	NYSE:ABBV	AbbVie Inc
10/29/2021	11:54AM	Dow Jones News	AbbVie Shares Up After Earnings Beat and Guidance Boost	NYSE:ABBV	AbbVie Inc
10/29/2021	9:08AM	TipRanks	AbbVie’s ABBV-951 Phase 3 Study Reflects Optimism; Shares Rise	NYSE:ABBV	AbbVie Inc
10/29/2021	8:54AM	Dow Jones News	AbbVie to Seek FDA Nod for Vraylar as Adjunct Treatment for Major Depressive Disorder	NYSE:ABBV	AbbVie Inc
10/29/2021	8:41AM	Dow Jones News	AbbVie Boosts Quarterly Dividend by 8.5%	NYSE:ABBV	AbbVie Inc
10/29/2021	8:29AM	Dow Jones News	AbbVie Boosts 2021 Earnings Forecast	NYSE:ABBV	AbbVie Inc
10/29/2021	7:50AM	PR Newswire (US)	AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder	NYSE:ABBV	AbbVie Inc
10/29/2021	7:43AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
10/29/2021	7:40AM	PR Newswire (US)	AbbVie Reports Third-Quarter 2021 Financial Results	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Next >>

Ethema Health (PK)

1812 Brewing (PK)

Anavex Life Sciences

Northwest Biotherapeutics (QB)

Intergrated Cannabis Sol... (PK)

Digital Brand Media and ... (PK)

Lightwave Logic

Impact Fusion (PK)

Kraig Biocraft Laborator... (QB)

Fannie Mae (QB)

Rennova Health (PK)

Delayed Upgrade Clock